Ligand-Independent Androgen Receptor Activity
The androgen receptor (AR) is important for the growth and survival of normal and malignant prostate cells. As such, androgen-deprivation therapy is the current mainstay of systemic prostate cancer therapy. Invariably, prostate cancer will develop resistance to androgen deprivation and recur with a “castration-recurrent” phenotype. The surprising finding that castration-recurrent prostate cancer is still reliant on AR activity indicates that novel means of targeting the AR could be developed to treat this stage of the disease. Several mechanisms, including ligand-independent activation, have been described as means by which the AR can achieve a critical level of activity in castration-recurrent prostate cancer. This chapter will explore the mechanisms of ligand-independent AR activation and highlight some recent findings generated in the Tindall laboratory.
KeywordsProstate Cancer Androgen Receptor LNCaP Cell Androgen Receptor Expression Androgen Receptor Gene
- Bain DL, Heneghan AF, Connaghan-Jones KD, Miura MT (2006). Nuclear receptor structure: implications for function. Annu Rev Physiol 69 Google Scholar
- Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD(2001a). Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7: 1273–81Google Scholar
- Haag P, Bektic J, Bartsch G, Klocker H, Eder IE(2005). Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 24: 24Google Scholar
- Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cussenot Oet al.(2001). Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61: 1919–26PubMedGoogle Scholar
- Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC(2003a). Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 9: 370–6Google Scholar